These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 10589756)

  • 1. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
    O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
    Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
    Pendyala L; Creaven PJ; Porter CW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
    Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
    Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture.
    Glikman P; Manni A; Demers L; Bartholomew M
    Cancer Res; 1989 Mar; 49(6):1371-6. PubMed ID: 2493979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells.
    Jun JY; Griffith JW; Bruggeman R; Washington S; Demers LM; Verderame MF; Manni A
    Breast Cancer Res Treat; 2007 Sep; 105(1):29-36. PubMed ID: 17143592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
    Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
    Weeks RS; Vanderwerf SM; Carlson CL; Burns MR; O'Day CL; Cai F; Devens BH; Webb HK
    Exp Cell Res; 2000 Nov; 261(1):293-302. PubMed ID: 11082299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
    Sunkara PS; Rosenberger AL
    Cancer Res; 1987 Feb; 47(4):933-5. PubMed ID: 3100031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
    Xu H; Washington S; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis.
    Horn Y; Spigel L; Marton LJ
    J Surg Oncol; 1989 Jul; 41(3):177-82. PubMed ID: 2501593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.
    Wolff AC; Armstrong DK; Fetting JH; Carducci MK; Riley CD; Bender JF; Casero RA; Davidson NE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5922-8. PubMed ID: 14676116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
    Ajani JA; Ota DM; Grossie VB; Levin B; Nishioka K
    Cancer Res; 1989 Oct; 49(20):5761-5. PubMed ID: 2507135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
    Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
    Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
    Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
    Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
    Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
    Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells.
    Jun JY; Griffith JW; Bruggeman R; Washington S; Demers LM; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Jan; 107(1):33-40. PubMed ID: 17333337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.